Navigating issues with your continuous glucose monitor (CGM)
Breakthrough T1D created a guide for sensor issues, from what to do if symptoms and CGM reading do not match to how to get a replacement.
Civica’s affordable long-acting insulin now available!
Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]
Q&A with San Diego Padres Pitcher Mason Miller
Breakthrough T1D sat down with Mason Miller to learn more about his journey with type 1 diabetes and the impact it has on him as an athlete.
Hot off the press: Continuous ketone monitoring guidelines are here
What’s happening? Continuous ketone monitoring (CKM) is on its way. A new paper in The Lancet Diabetes & Endocrinology, titled “International expert recommendations on the application and utility of continuous ketone monitoring for people with diabetes,” was published by Breakthrough T1D and expert collaborators, spearheaded by our Chief Medical Officer, International, Thomas Danne, M.D., Ph.D. […]
Support and resources for your CGM
Support and resources for issues with continuous glucose monitors (CGMs), including inaccurate readings and faulty sensors.
2025 Top T1D advances: Full speed ahead
How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]
Smart devices, angry skin: The underside of diabetes tech
Skin reactions from adhesives on insulin pumps and CGMs are common. Learn why they occur and how to reduce irritation.
Demystifying the pipeline of T1D therapies and devices: Turning ideas into reality
What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]
See our community. See T1D.
Building awareness and understanding about T1D is more important than ever. Together, our stories change how people see T1D.
Two truths and a lie: Separate T1D facts from fiction
There are a lot of commonly believed myths about type 1 diabetes (T1D). Play our game to separate fact from fiction.
